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Purpose Fluourouracil (FU) is a mainstay of chemotherapy, although toxicities are
common. Genetic biomarkers have been used to predict these adverse events, but
their utility is uncertain.Patients and Methods We tested candidate polymorphisms
identified from a systematic literature search for associations with capecitabine
toxicity in 927 patients with colorectal cancer in the Quick and Simple and Reliable
trial (QUASAR2). We then performed meta-analysis of QUASAR2 and 16 published
studies (n = 4,855 patients) to examine the polymorphisms in various FU
monotherapy and combination therapy regimens. Results Global capecitabine toxicity
(grades 0/1/2 v grades 3/4/5) was associated with the rare, functional DPYD alleles
2846T>A and *2A (combined odds ratio, 5.51; P = .0013) and with the common
TYMS polymorphisms 5′VNTR2R/3R and 3′UTR 6bp ins-del (combined odds ratio,
1.31; P = 9.4 × 10−6). There was weaker evidence that these polymorphisms predict
toxicity from bolus and infusional FU monotherapy. No good evidence of association
with toxicity was found for the remaining polymorphisms, including several currently
included in predictive kits. No polymorphisms were associated with toxicity in
combination regimens. Conclusion A panel of genetic biomarkers for capecitabine
monotherapy toxicity would currently comprise only the four DPYD and TYMS
variants above. We estimate this test could provide 26% sensitivity, 86% specificity,
and 49% positive predictive value—better than most available commercial kits, but
suboptimal for clinical use. The test panel might be extended to include additional,
rare DPYD variants functionally equivalent to *2A and 2846A, though insufficient
evidence supports its use in bolus, infusional, or combination FU. There remains a
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